Aster DM Healthcare to construct Rs 400 crore hospital in Chennai

KOCHI: Aster DM Healthcare, a leading healthcare service provider in India and in GCC with presence in 9 countries, has entered into an agreement with Subramanya Constructions & Development Company Limited (SCDC), to construct a new hospital in Chennai.

This 500 bedded, multi-specialty hospital is expected to be commissioned in 2020. The total project cost of the hospital is estimated at Rs 400 crore.

Aster DM Healthcare operates 11 hospitals in South India with 4037 installed beds. Commenting on the expansion into the Chennai healthcare market, founder chairman and managing director of Aster DM Healthcare, Azad Moopen said, “Looking at the demand supply gap, there is a requirement for more hospitals in India in general and in Chennai in particular. With our presence in Kerala, Karnataka, Telangana, Andhra and Maharashtra, we believe that our presence in Tamil Nadu would benefit patients in the country. We also see India as a key market for Aster DM Healthcare in future.”

“With our current diversified asset portfolios in Southern and Western India, Tamil Nadu was the only State without our presence. This new flagship hospital due to be commissioned in 2020 will offer state-of-the-art quaternary care services to the people of Tamil Nadu and fulfil the current gap within our network,” said Harish Pillai, CEO, Aster Hospitals & Clinics (India).

Aster DM Healthcare is present in the Middle East, India and the Philippines with a large number of health facilities including 20 hospitals and 98 clinics.

  • Related Posts

    Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

    Bharat Mandapam witnessed Spectacle of Crazy Innovations by Maker of Ssi Mantra, Best in class Surgical Robot New Delhi: It was a veritable display of innovative potential and prowess of…

    On World Health Day ‘CAHO Na Patient Se Pyaar Hai’

    Chennai hosts 3 Day International Conference CAHOCON on Patient Safety in Hospitals starting April 10 New Delhi:  Patient safety in hospitals is a global concern, more so in India. It…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

    ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

    Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

    Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

    Obesity drug market to gain as Indians pop the pill and Chinese bring more

    Obesity drug market to gain as Indians pop the pill and Chinese bring more

    Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

    Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

    Boehringer Ingelheim launches AI centre for pharma research in London

    Boehringer Ingelheim launches AI centre for pharma research in London

    Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

    Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March